Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital & Harvard Medical School, Boston, USA.
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital & Harvard Medical School, Boston, USA.
Ann Oncol. 2019 Feb 1;30(2):274-280. doi: 10.1093/annonc/mdy488.
Hospitalized patients with cancer experience a high symptom burden, which is associated with poor health outcomes and increased health care utilization. However, studies investigating symptom monitoring interventions in this population are lacking. We conducted a pilot randomized trial to assess the feasibility and preliminary efficacy of a symptom monitoring intervention to improve symptom management in hospitalized patients with advanced cancer.
We randomly assigned patients with advanced cancer who were admitted to the inpatient oncology service to a symptom monitoring intervention or usual care. Patients in both arms self-reported their symptoms daily (Edmonton Symptom Assessment System and Patient Health Questionnaire-4). Patients assigned to the intervention had their symptom reports presented graphically with alerts for moderate/severe symptoms during daily team rounds. The primary end point of the study was feasibility. We defined the intervention as feasible if >75% of participants hospitalized >2 days completed >2 symptom reports. We observed daily rounds to determine whether clinicians discussed and developed a plan to address patients' symptoms. We used regression models to assess intervention effects on patients' symptoms throughout their hospitalization, readmission risk, and hospital length of stay (LOS).
Among 150 enrolled patients (81.1% enrollment), 94.2% completed >2 symptom reports. Clinicians discussed 60.4% of the symptom reports and developed a plan to address the symptoms highlighted by the symptom reports 20.8% of the time. Compared with usual care, intervention patients had a greater proportion of days with lower psychological distress (B = 0.12, P = 0.008), but no significant difference in the proportion of days with improved Edmonton Symptom Assessment System-physical symptoms (B = 0.07, P = 0.138). Intervention patients had lower readmission risk (hazard ratio = 0.68, P = 0.224), although this difference was not significant. We found no significant intervention effects on hospital LOS (B = 0.16, P = 0.862).
This symptom monitoring intervention is feasible and demonstrates encouraging preliminary efficacy for improving patients' symptoms and readmission risk.ClinicalTrials.gov identifier NCT02891993.
住院癌症患者的症状负担较高,这与不良健康结局和增加医疗保健利用有关。然而,在该人群中,研究调查症状监测干预措施的研究还很缺乏。我们进行了一项试点随机试验,以评估一种症状监测干预措施改善晚期癌症住院患者症状管理的可行性和初步疗效。
我们将住院肿瘤科的晚期癌症患者随机分配到症状监测干预组或常规护理组。两组患者均每日报告症状(埃德蒙顿症状评估系统和患者健康问卷-4)。分配到干预组的患者,其症状报告以图形方式呈现,并在每日团队查房时对中度/重度症状发出警报。该研究的主要终点是可行性。如果 >75%住院 >2 天的参与者完成 >2 次症状报告,则将干预定义为可行。我们观察每日查房,以确定临床医生是否讨论并制定了针对患者症状的计划。我们使用回归模型评估干预对患者住院期间症状、再入院风险和住院时间(LOS)的影响。
在纳入的 150 名患者(81.1%的入组率)中,94.2%完成了 >2 次症状报告。临床医生讨论了 60.4%的症状报告,并制定了处理症状报告中突出症状的计划,占 20.8%的时间。与常规护理相比,干预组患者心理困扰天数比例更高(B=0.12,P=0.008),但埃德蒙顿症状评估系统-身体症状改善天数比例无显著差异(B=0.07,P=0.138)。干预组患者再入院风险较低(风险比=0.68,P=0.224),但差异无统计学意义。我们没有发现干预对住院 LOS 有显著影响(B=0.16,P=0.862)。
这种症状监测干预措施是可行的,并且为改善患者症状和再入院风险提供了令人鼓舞的初步疗效。临床试验.gov 标识符 NCT02891993。